Efficacy of selpercatinib as tyrosine kinase inhibitor in RETmutant medullary thyroid cancer: a systematic review

被引：0
|
作者：
Margouw, R. Relia [1 ]
Santoso, A. Febrian [1 ]
Maulidia, S. Azrianindita [1 ]
Kurniawan, A. [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO4-5
引用
收藏
页码：S1330 / S1330
页数：1
相关论文
共 50 条
  • [1] Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.
    Chowdry, R. P.
    Bhimani, C.
    Ramalingam, S. S.
    Khuri, F. R.
    Owonikoko, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer
    Strock, CJ
    Park, JI
    Rosen, DM
    Ruggeri, B
    Denmeade, SR
    Ball, DW
    Nelkin, BD
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01): : 79 - 84
  • [3] Neoadjuvant selpercatinib for advanced medullary thyroid cancer
    Jozaghi, Yelda
    Zafereo, Mark
    Williams, Michelle D.
    Gule-Monroe, Maria K.
    Wang, Jennifer
    Grubbs, Elizabeth G.
    Vaporciyan, Ara
    Hu, Mimi I.
    Busaidy, Naifa
    Dadu, Ramona
    Waguespack, Steven G.
    Subbiah, Vivek
    Cabanillas, Maria
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (01): : E7 - E12
  • [4] Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma
    Shankar, Ananth
    Kurzawinski, Tom
    Ross, Emma
    Stoneham, Sara
    Beale, Tim
    Proctor, Ian
    Hulse, Tony
    Simpson, Kate
    Gaze, Mark N.
    Cattaneo, Elene
    Gevers, Evelien
    Marshall, Lynley
    Hubbard, Johnathan G.
    Brain, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 158 : 38 - 46
  • [5] Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis
    Oba, Takaaki
    Chino, Tatsunori
    Soma, Ai
    Shimizu, Tadafumi
    Ono, Mayu
    Ito, Tokiko
    Kanai, Toshiharu
    Maeno, Kazuma
    Ito, Ken-ichi
    ENDOCRINE JOURNAL, 2020, 67 (12) : 1215 - 1226
  • [6] Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
    Hadoux, Julien
    Schlumberger, Martin
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 31 (03) : 335 - 347
  • [7] Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    Kurzrock, Razelle
    Sherman, Steven I.
    Ball, Douglas W.
    Forastiere, Arlene A.
    Cohen, Roger B.
    Mehra, Ranee
    Pfister, David G.
    Cohen, Ezra E. W.
    Janisch, Linda
    Nauling, Forlisa
    Hong, David S.
    Ng, Chaan S.
    Ye, Lei
    Gagel, Robert F.
    Frye, John
    Mueller, Thomas
    Ratain, Mark J.
    Salgia, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2660 - 2666
  • [8] TYROSINE KINASE INHIBITORS (TKI) FOR THE TREATMENT OF ADVANCED MEDULLARY THYROID CARCINOMA: A SYSTEMATIC REVIEW AND INDIRECT COMPARISON
    Kawalec, P.
    VALUE IN HEALTH, 2016, 19 (07) : A708 - A708
  • [9] Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer
    Meng, Shu
    Wu, Hongyan
    Wang, Jing
    Qiu, Qiyuan
    MOLECULAR INFORMATICS, 2016, 35 (10) : 495 - 505
  • [10] Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer
    Pitoia, Fabian
    Trimboli, Pierpaolo
    Abelleira, Erika
    ENDOCRINE, 2024, 86 (01) : 109 - 113
12345